Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-04
2011-01-04
Shafer, Shulamith H. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C424S185100
Reexamination Certificate
active
07863240
ABSTRACT:
The present invention relates to methods for the modulation of immune responses. More particularly, the invention relates to methods and uses of leptin for immuno-modulation of the balance between the Th1/Th2 responses and for the treatment of immune-related disorders. Specifically, the methods of the invention comprise shifting the Th1/Th2 cell balance towards the proinflammatory state. This modulation of the cell balance may be performed by increasing the activity and/or the expression of leptin in said subject, for instance by raising the amount of leptin. The amount of leptin in a subject may be increased by activating immunoregulatory cells, administering an immunomodulatory amount of leptin or a homologue, derivative, or functional fragment of leptin.
REFERENCES:
patent: 7109159 (2006-09-01), Barkan et al.
patent: 2005/0176787 (2005-08-01), Bauer et al.
patent: 99/40946 (1999-08-01), None
Bowie et al, 1990, Science 247:1306-1310.
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds, Birkhauser, Boston, pp. 433-506.
Bernotienne et al. (2006. Arthritis Research and Therapy. 8:217.
Wang et al. 2004. World J Gastroenterology 10:2478-2481.
Somasundar et al. 2004. Journal of Surgical Research 116:337-349.
Lago et al. 2008. Cellular Immunol. 252:139-145.
Citron et al. 2003. J Clin Oncol. 21:1-9.
Grasso et al., “In Vivo Effects of Leptin-Related Synthetic Peptides on Body Weight and Food Intake in Female ob/ob Mice: Localization of Leptin Activity to Domains Between Amino Acid Residues 106-140”, Endocrinology, 1997, pp. 1413-1418, vol. 138, No. 4, U.S.A.
Hu et al., “Leptin—A Growth Factor in Normal and Malignant Breast Cells and for Normal Mammary Gland Development”, Journal of the National Cancer Institute, Nov. 20, 2002, pp. 1704-1711, vol. 94, No. 22.
Laud et al., “Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line”, Molecular and Cellular Endocrinology, 2002, pp. 219-226, vol. 188, Elsevier Science Ireland Ltd.
Muller et al., “Leptin Impairs Metabolic Actions of Insulin in Isolated Rat Adipocytes”, The Journal of Biological Chemistry, Apr. 18, 1997, pp. 10585-10593, vol. 272, No. 16, U.S.A.
Okumura et al., “Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-a and PPAR expression”, Biochimica et Biophysica Acta, 2002, pp. 107-116, vol. 1592, Elsevier Science B.V.
Saxena et al., “Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells”, Cancer Research, Mar. 15, 2007, pp. 2497-2507, vol. 67, No. 6.
Soma et al., “Leptin Augments Proliferation of Breast Cancer Cells via Transactivation of HER2”, Journal of Surgical Research, 2007, pp. 9-14, vol. 149, Elsevier Inc.
Szanto et al., “Selective interaction between leptin and insulin signaling pathways in a hepatic cell line”, PNAS, Feb. 29, 2000, pp. 2355-2360, vol. 97, No. 5.
Yin et al., “Molecular Mechanisms Involved in the Growth Stimulation of Breast Cancer Cells by Leptin”, Cancer Research, Aug. 15, 2004, pp. 5870-5875, vol. 64.
Sarraf et al., “Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia”, The Journal of Experimental Medicine, Jan. 6, 1997, pp. 171-175, vol. 185, No. 1.
Slieker et al., “Regulation of Expression of ob mRNA and Protein by Glucocorticoids and cAMP”, The Journal of Biological Chemistry, Mar. 8, 1996, pp. 5301-5304, vol. 271, No. 10, U.S.A.
de Vos et al., “Induction of ob Gene Expression by Corticosteroids is Accompanied of Body Weight Loss and Reduced Food Intake”, The Journal of Biological Chemistry, Jul. 7, 1995, pp. 15958-15961, vol. 270, No. 27, U.S.A.
Chen et al., “Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway”, Endocrine-Related Cancer, 2007, pp. 513-529, vol. 14.
Dieudonne et al., “Leptin medicates a proliferative response in human MCF7 breast cancer cells”, Biochemical and Biophysical Research Communication, 2002, pp. 622-628, vol. 293, Elsevier Science.
Garofalo et al., “Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells”, Clinical Cancer Research, Oct. 1, 2004, pp. 6466-6475, vol. 10.
Grasso et al., “Inhibitory Effects of Leptin-Related Synthetic Peptide 116-130 on Food Intake and Body Weight Gain in Female C57BL/6J ob/ob Mice May Not Be Mediated by Peptide Activation of the Long Isoform of the Leptin Receptor”, Diabetes, Nov. 1999, pp. 2204-2209, vol. 98.
Rozhavskaya-Arena et al., “Design of Synthetic Leptin Agonist: Effects on Energy Balance, Glucose Homeostasis, and Thermoregulation”, Endocrinology, 2000, pp. 2501-2507, vol. 141, No. 7, U.S.A.
Faggioni et al., “IL-IB mediates leptin induction during inflammation”, Am J Physiol Regulatory Integrative Comp Physiol, 1998, pp. 204-208, vol. 274.
Wang et al., “A nutrient-sensing pathway regulates leptin gene expression in muscle and fat”, Nature, Jun. 18, 1998, pp. 684-688, vol. 393, No. 6686.
Lee et al., “The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amine with leptine-like activity, in male C57BL/6J mice”, Regul Pept, Oct. 9, 2008, pp. 1-3, vol. 150.
Cohen et al., “Modulation of Insulin Activities by Leptin”, Science Magazine, Nov. 15, 1996, pp. 1185-1188, vol. 274, No. 5290.
Zhang et al., “Crystal structure of the obese protein leptin-E100”, Nature, May 8, 1997, pp. 206-209, vol. 387, No. 6629.
Elinav Eran
Ilan Yaron
Bogdanos, Esq. Natalie
Carden, Esq. Kellie L.
Enzo Therapeutics, Inc.
Shafer Shulamith H.
LandOfFree
Methods and uses of leptin in hepatocellular carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and uses of leptin in hepatocellular carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and uses of leptin in hepatocellular carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675414